Uveal Melanoma
Recent clinical, regulatory, research and industry developments relating to this disease.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2027.
- 2 industry developments reported.
- Q3 2027Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal Melanoma
- Q1 2030A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Q4 2030A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
- Q4 2032Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)
Clinical MilestonesViewHide
- 2026-06-30Adjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)Results expected Q4 2032
- 2026-06-12Neoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal MelanomaResults expected Q3 2027
- 2026-05-06A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)Results expected Q4 2030
- 2026-04-02A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaResults expected Q1 2030
Industry & MarketViewHide
- 2026-08-24Repeat Gene Expression Profiling, PRAME Status, and Next-Generation Sequencing Testing in Uveal Melanoma Undergoing Secondary TherapyIndustry · American Journal of Ophthalmology
- 2026-02-23CRISPR-Cas13d-mediated targeting of RasGRP3 shows selective anticancer effects in uveal melanomaIndustry · BioWorld Gene Therapy
- 2026-08-24IndustryRepeat Gene Expression Profiling, PRAME Status, and Next-Generation Sequencing Testing in Uveal Melanoma Undergoing Secondary TherapyIndustry · American Journal of Ophthalmology
- 2026-07-09ClinicalA Phase II, Monocentric, Single Arm Trial Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma PatientsCompleted
- 2026-06-30ClinicalAdjuvant Tebentafusp (IMCgp100) Versus Observation in HLA-A*02:01 Positive Patients Following Definitive Treatment of High-risk Uveal Melanoma: an EORTC Randomized Phase III Study (ATOM Trial)Results expected Q4 2032
- 2026-06-12ClinicalNeoadjuvant Tebentafusp in Patients With Locally Advanced, Unresectable Primary Uveal MelanomaResults expected Q3 2027
- 2026-05-06ClinicalA Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)Results expected Q4 2030
- 2026-04-02ClinicalA Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaResults expected Q1 2030
- 2026-02-23IndustryCRISPR-Cas13d-mediated targeting of RasGRP3 shows selective anticancer effects in uveal melanomaIndustry · BioWorld Gene Therapy
- 2026-02-11ClinicalA Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal MelanomaResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A… (2022)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Melanoma4
- Uveal Neoplasms4
- Antineoplastic Combined Chemotherapy Protocols1
- Choroid Neoplasms1
- Circulating Tumor DNA1
- DNA Methylation1
- Gene Expression Regulation, Neoplastic1
- Immune Checkpoint Inhibitors1
Leading journals5
- Cancer cell1
- Frontiers in immunology1
- Nature communications1
- Ophthalmology1
- The New England journal of medicine1
Leading researchers8
- Coupland SE2
- Hassel JC2
- Piperno-Neumann S2
- Roman-Roman S2
- Stern MH2
- Abdel-Rahman MH1
- Akbani R1
- Babur O1
Affiliations (unnormalised)6
- Institut Curie2
- University Hospital Essen2
- Bavarian Cancer Research Center (BZKF)1
- Buck Institute for Research on Aging1
- Canada's Michael Smith Genome Sciences Centre1
- Center for Biomolecular Sciences and Engineering1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Uveal melanoma is a rare malignant melanoma that arises from melanocytes in the uvea of the eye. It is an ocular melanoma rather than a cutaneous melanoma, and the literature focuses on its biology, prognosis, and treatment approaches.
The supplied grounding does not identify a specific cause or aetiology for uveal melanoma. It only defines the disease as a malignant melanoma arising from uveal melanocytes.
The disease originates from malignant transformation of melanocytes in the uveal tract. The grounding does not provide additional mechanistic detail about molecular drivers or downstream biological pathways.
The supplied grounding does not specify risk factors for uveal melanoma.
The supplied grounding does not provide treatment guidance or standard-of-care modalities for uveal melanoma.
AI-generated summary grounded in MeSH. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
A rare, malignant MELANOMA arising from the melanocytes of the UVEA.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.